Physician profile
Daniel Ridout
NPI 1265427504
$1,804.71
in general payments reported to CMS, 2019-2025
16 companies · $674 in 2025
The $674 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $91.87 · 2021: $164 · 2022: $231 · 2023: $215 · 2024: $246 · 2025: $674.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,073 · Education: $62.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,072.64 |
| Education | $62.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $745.16 | 2019-2025 | |
| Gilead Sciences, INC. | $335.15 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $99.29 | 2019-2024 | Ocaliva |
| Axonics, INC. | $88.65 | 2021-2023 | Axonics |
| Merck Sharp & Dohme LLC | $85.62 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.33 | 2019-2025 | Entyvio |
| Pfizer INC. | $62.00 | 2025 | |
| Ardelyx, INC. | $56.04 | 2024-2025 | Ibsrela |
| Janssen Biotech, INC. | $51.64 | 2023-2024 | Tremfya, Stelara |
| Ipsen Biopharmaceuticals, INC | $40.05 | 2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $37.15 | 2024 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $35.37 | 2025 | Dupixent |
| Celgene Corporation | $33.21 | 2023 | Zeposia |
| Madrigal Pharmaceuticals | $18.42 | 2025 | Rezdiffra |
| Redhill Biopharma INC. | $16.52 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $16.11 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ridout listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.